Local
Akeso Announces NMPA Acceptance of sNDA for Ivonescimab in Combination with Chemotherapy for First-Line Biliary Tract Cancer
Meet in Common connects news with real conversations. Use ThinkMatch to arrange a Roundtable and meet people to discuss this story.
Roundtables are designed for groups of four, with a shared subject and room for everyone to speak. Come for discussion, with no dating expectation.
Source: Newnan Times-Herald

HONG KONG, Nov. 16, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental New Drug Application (sNDA) for ivonescimab in combination with chemotherapy for the…
This excerpt comes from the named source. Read the original for the full reporting.
Read the original at Newnan Times-Herald



